DOI: 10.1186/s13550-018-0358-8Pages: 1-9

Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody

1. VU University Medical Center, Department of Hematology

2. VU University Medical Center, Department of Radiology and Nuclear Medicine

3. Roche Innovation Center, Department of Pharma Research and Early Development

4. Safety Risk Management, Department of Product Development

5. Roche Innovation Center, Department of Pharma Research and Early Development

6. VU University Medical Center, Department of Medical Oncology

Correspondence to:
Yvonne W. S. Jauw
Tel: +31 20 4442604
Email: yws.jauw@vumc.nl

Close

Abstract

Background

Ideally, monoclonal antibodies provide selective treatment by targeting the tumour, without affecting normal tissues. Therefore, antibody imaging is of interest, preferably in early stages of drug development. However, the imaging signal consists of specific, as well as non-specific, uptake. The aim of this study was to assess specific, target-mediated uptake in normal tissues, with immuno-PET in a phase I dose escalation study, using the anti-CD44 antibody RG7356 as example.

Results

Data from thirteen patients with CD44-expressing solid tumours included in an imaging sub-study of a phase I dose escalation clinical trial using the anti-CD44 antibody RG7356 was analysed. 89Zirconium-labelled RG7356 (1 mg; 37 MBq) was administered after a variable dose of unlabelled RG7356 (0 to 675 mg). Tracer uptake in normal tissues (liver, spleen, kidney, lung, bone marrow, brain and blood pool) was used to calculate the area under the time antibody concentration curve (AUC) and expressed as tissue-to-blood AUC ratios.

Within the dose range of 1 to 450 mg, tissue-to-blood AUC ratios decreased from 10.6 to 0.75 ± 0.16 for the spleen, 7.5 to 0.86 ± 0.18 for the liver, 3.6 to 0.48 ± 0.13 for the bone marrow, 0.69 to 0.26 ± 0.1 for the lung and 1.29 to 0.56 ± 0.14 for the kidney, indicating dose-dependent uptake. In all patients receiving ≥ 450 mg (n = 7), tumour uptake of the antibody was observed.

Conclusions

This study demonstrates how immuno-PET in a dose escalation study provides a non-invasive technique to quantify dose-dependent uptake in normal tissues, indicating specific, target-mediated uptake.

This article is freely available, click here to access the full text/PDF

  • Accepted: Jan 8, 2018
  • Online: Jan 22, 2018

Article Tools

eanm
EJNMMI Ad